GlaxoSmithKline`s Nucala (Mepolizumab) gets European Approval for use in Three Additional Eosinophil-driven Diseases.
KEYPOINTS: GlaxoSmithKline (NYSE:GSK) announces that the European Commission has approved Nucala (Mepolizumab), a monoclonal antibody that targets interleukin-5, for use in three…